VA
MIST icon

VR Adviser’s Milestone Pharmaceuticals MIST Stock Holding History

VR Adviser’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-925,048
Closed -$1.54M – 40
2023
Q4 		$1.54M Sell
925,048
-1,283,764
-58% -$3.48M 0.11% 35
2023
Q3 		$6.85M Hold
2,208,812
– – 0.72% 30
2023
Q2 		$6.3M Hold
2,208,812
– – 1.01% 21
2023
Q1 		$8.7M Hold
2,208,812
– – 1.7% 17
2022
Q4 		$8.75M Sell
2,208,812
-216,925
-9% -$1.14M 1.47% 19
2022
Q3 		$22.3M Buy
+2,425,737
New +$18.4M 3.44% 8

Other funds holding MIST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser's MIST Position: Q1 2024 in Review

VR Adviser sold out of Milestone Pharmaceuticals (MIST) in Q1 2024, closing a stake of 925,048 shares — an estimated $1.54M sold.

VR Adviser first reported a position in MIST in Q3 2022 and held it in 6 quarters. The position peaked at $22.3M in Q3 2022. 44 funds tracked by Wall St. Rank hold MIST as of Q1 2024.

  • VR Adviser reported no remaining Milestone Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • VR Adviser sold 925,048 Milestone Pharmaceuticals shares in Q1 2024, an estimated $1.54M.
  • VR Adviser first reported a position in Milestone Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • VR Adviser's Milestone Pharmaceuticals position peaked at $22.3M in Q3 2022.
  • 44 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2024.

Based on VR Adviser's 13F filing for Q1 2024, filed 15 May 2024.